New Drug Discovery in Hematology

Advancing novel therapeutic agents for the treatment of malignancy into the marketplace is an increasingly costly and lengthy process. As such, new strategies for drug discovery are needed. Drug repurposing represents an opportunity to rapidly advance new therapeutic strategies into clinical trials at a relatively low cost. Known on-patent or off-patent drugs with unrecognized anticancer activity can be rapidly advanced into clinical testing for this new indication by leveraging their known pharmacology, pharmacokinetics, and toxicology. Using this approach, academic groups can participate in the drug discovery field and smaller biotechnology companies can “de-risk” early-stage drug discovery projects. Here, several scientific approaches used to identify drug repurposing opportunities are highlighted, with a focus on hematologic malignancies. In addition, a discussion of the regulatory issues that are unique to drug repurposing and how they impact developing old drugs for new indications is included. Finally, the mechanisms to enhance drug repurposing through increased collaborations between academia, industry, and non-profit charitable organizations are discussed.
·        Hematopoietic Cells Mobilization
·        Patient-reported outcomes in drug development
·        De novo drug discovery
·        Drug Repurposing
·        Clinical trials
·        Future directions and conclusions

 

    Related Conference of New Drug Discovery in Hematology

    October 23-24, 2019

    13th World Congress on Hematology and Oncology

    | Tokyo, Japan

    17th World Hematology Congress

    November 25-26, 2019 Paris, France
    March 16-17, 2020

    18th World Hematology Congress

    London, UK

    New Drug Discovery in Hematology Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in